






A**B****C**





Supplementary Figure 1

In vitro growth features of IOR/CAR cells silenced for CD99. (A) Stable transfection of IOR/CAR cells results in a substantial reduction of CD99 protein. (B) CD99 expression in derived IOR/CAR clones by cytofluorometry. (C) β -III Tubulin expression in CD99-silenced cells. Percentage of neurite-bearing IOR/CAR-derived cells are reported.






Supplementary Figure 2

Analysis of SRE, E2F, CREB, AP1 activity in (A) TC-CD99-shRNA and (B) CAR-CD99-shRNA models. Fold increase of reporters transcriptional activity are expressed as ratio between luciferase activity of clones and luciferase activity of parental cell line. Graphs summarize results of three independent experiments performed in triplicate. (Mean \pm SEM).

A**B****C****D**


Supplementary Figure 3

Quality control of experimental models assessed by western blot analysis.



A**B****C**

Supplementary Figure 4

(A) NF-κB subunits were evaluated by PCR in TC-CD99-shRNA and CAR-CD99-shRNA models. (B) NF-κBp65 expression upon treatment with TNF α 1ng/ml for 4h. (C) NF-κB transcriptional activity in TC-71 and IOR/CAR cells in presence or absence of CD99 after treatment with TNF α 1ng/ml for 4h (Mean \pm SEM *p Value < 0.05).



B



Supplementary Figure 5

(A) Analysis by q-RT-PCR of miR-34a in TC-71 overexpressing model (*p Value <0.05) (B) Analysis of Notch pathway protein (left panel) and HEY-1 mRNA (right panel) levels in TCpMIF empty vector or TCpMIF miR-34a.